Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES‐34)
Open Access
- 5 June 2006
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 23 (2), 127-134
- https://doi.org/10.1002/dmrr.658
Abstract
Aim To compare the prevalence of metabolic syndrome (MS) using the World Health Organisation (WHO), Adult Treatment Panel III (ATPIII) and International Diabetes Federation (IDF) criteria of MS in an urban south Indian population, and their ability to identify coronary artery disease (CAD) in males and females. Methods Chennai Urban Rural Epidemiology Study (CURES) is one of the largest epidemiological studies on diabetes carried out in India, in which 26 001 individuals aged ≥20 years were screened using systematic random sampling method. Every tenth subject recruited in Phase 1 of CURES was requested to participate in Phase 3, and the response rate was 90.4%. An oral glucose tolerance test (OGTT) was performed in all individuals except self‐reported diabetic subjects. Anthropometric measurements and lipid estimations were done in all subjects and the prevalence of MS estimated using the three criteria. Diagnosis of CAD, made by resting 12 lead ECG, was compared by the three criteria of MS. Results MS was identified in 546 subjects (23.2%) by WHO criteria, 430 subjects (18.3%) by ATPIII criteria and 607 subjects (25.8%) by IDF criteria. Only 224 of these subjects were identified by all the three criteria. There was an increased risk of probable CAD in MS subjects diagnosed by WHO criteria (odds ratio (OR) 3.86, 95% Confidence Interval (CI), 2.37–6.29, p < 0.001), compared to ATPIII criteria (OR 2.19, 95% CI 1.30–3.67, p < 0.05) and IDF criteria (OR 1.90, 95% CI 1.16–3.12, p < 0.05). The WHO criteria marked out a much higher population for CAD risk compared to ATPIII and IDF criteria in males, but not in females. Conclusion In Asian Indians, the WHO, ATPIII and IDF criteria of MS identify different individuals. The WHO criteria identify a greater number of CAD subjects in males, but not in females. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 33 references indexed in Scilit:
- Concordance Between the 2005 International Diabetes Federation Definition for Diagnosing Metabolic Syndrome With the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization DefinitionsDiabetes Care, 2005
- High prevalence of metabolic syndrome in Hong Kong Chinese—comparison of three diagnostic criteriaDiabetes Research and Clinical Practice, 2005
- Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn StudyCell Metabolism, 2005
- The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohortDiabetes/Metabolism Research and Reviews, 2005
- The metabolic syndrome: prevalence and risk factors in the urban population of Ho Chi Minh CityDiabetes Research and Clinical Practice, 2005
- Prevalence of metabolic syndrome in an Indian urban populationInternational Journal of Cardiology, 2004
- Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease?Diabetes Care, 2004
- The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese populationDiabetes Research and Clinical Practice, 2004
- Can We Apply the National Cholesterol Education Program Adult Treatment Panel Definition of the Metabolic Syndrome to Asians?Diabetes Care, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001